Structure via PubChem · Public domain (PubChem)
miglitol
Sign in to saveAlso known as Glyset®, N-hydroxylethyl-1-deoxynojirimycin, Miglitolum
Miglitol is an oral alpha-glucosidase inhibitor used in the treatment of type 2 diabetes. It works by reversibly inhibiting alpha-glucosidase enzymes in the small intestine, which delays the digestion of complex carbohydrates and subsequently reduces postprandial glucose levels. Approved for clinical use since 1998, miglitol has demonstrated efficacy in improving glycemic control, reducing HbA1c levels, and decreasing both fasting and postprandial plasma glucose concentrations in long-term clinical trials. Additionally, recent studies have suggested that miglitol may have potential as an anti-
Chemical data
- Formula
- C8H17NO5
- Molecular weight
- 207.22 g/mol
- IUPAC name
- (2R,3R,4R,5S)-1-(2-hydroxyethyl)-2-(hydroxymethyl)piperidine-3,4,5-triol
- SMILES
- C1[C@@H]([C@H]([C@@H]([C@H](N1CCO)CO)O)O)O
- InChIKey
- IBAQFPQHRJAVAV-ULAWRXDQSA-N
- XLogP
- -2.6
- Polar surface area
- 104 Ų
- H-bond donors
- 5
- H-bond acceptors
- 6
- Formal charge
- 0
via PubChem
Research
426 papers- Miglitol.2012
- Miglitol.2006
- Miglitol: a review of its therapeutic potential in type 2 diabetes mellitus.Drugs · 2000
- Review: Miglitol has potential as a therapeutic drug against obesity.Nutrition & metabolism · 2015
- Miglitol, a new alpha-glucosidase inhibitor.Expert opinion on pharmacotherapy · 1999
via PubMed
Wikidata facts
- Mass
- 207.111
Show 5 more facts
- chemical formula
- C₈H₁₇NO₅
- canonical SMILES
- C1C(C(C(C(N1CCO)CO)O)O)O
- isomeric SMILES
- C1[C@@H]([C@H]([C@@H]([C@H](N1CCO)CO)O)O)O
- defined daily dose
- 0.3
- Commons category
- Miglitol
via Wikidata · CC0
~2 min read
Article
3 sectionsContents
- Formulation
- See also
- References
Miglitol is an oral alpha-glucosidase inhibitor used in the treatment of type 2 diabetes. It works by reversibly inhibiting alpha-glucosidase enzymes in the small intestine, which delays the digestion of complex carbohydrates and subsequently reduces postprandial glucose levels. Approved for clinical use since 1998, miglitol has demonstrated efficacy in improving glycemic control, reducing HbA1c levels, and decreasing both fasting and postprandial plasma glucose concentrations in long-term clinical trials. Additionally, recent studies have suggested that miglitol may have potential as an anti-obesity agent, showing promise in reducing body weight and body mass index in obese or diabetic patients. While generally well-tolerated, the most common side effects associated with miglitol are gastrointestinal disturbances, which are typically mild to moderate and tend to decrease over time.
It must be taken at the start of main meals to have maximal effect